# Vortex Therapeutics

Source: https://onco.cc/companies/vortex-therapeutics/  
OnCo record `vortex-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vortex Therapeutics is an Illinois company making tablets that block MYC, a protein that drives the growth of many cancers and has had no direct drug. Its lead medicine, VOR-001, is being prepared for first trials in people.

## Summary

Vortex Therapeutics, of Lombard, Illinois, develops small-molecule inhibitors of intrinsically disordered proteins. Its most advanced programme, VOR-001, is described as a direct, orally bioavailable small-molecule MYC inhibitor that the company has selected to advance to an investigational new drug application; the company reports tumour regression in a hepatocellular carcinoma model in mice and has developed a response signature for selecting patients. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a novel MYC inhibitor for cancer therapy (5R44CA302283-02, USD 1,142,245).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: VORTEX THERAPEUTICS INC
- HQ: Lombard, IL
- Type: biotech
- Website: https://vortextherapeutics.com/

## Notes

- Read on vortextherapeutics.com (home, science and pipeline pages) and the NIH RePORTER record on 4 November 2026. Efficacy and safety statements are the company's own preclinical findings.

## Sources

- Official website: https://vortextherapeutics.com/
- Pipeline: https://vortextherapeutics.com/pipeline-vortex-therapeutics/
- NIH RePORTER: 5R44CA302283-02: https://reporter.nih.gov/project-details/11419007

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [MYC](https://onco.cc/targets/myc-gene/)
- drugs: [VOR-001](https://onco.cc/drugs/vor-001/)

---
JSON: https://onco.cc/api/v1/entities/vortex-therapeutics.json